EG24073A - A novel crystalline form of n-(4-(2-amino-4,7 dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid and process thereof - Google Patents

A novel crystalline form of n-(4-(2-amino-4,7 dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid and process thereof

Info

Publication number
EG24073A
EG24073A EG20010167A EG20010167A EG24073A EG 24073 A EG24073 A EG 24073A EG 20010167 A EG20010167 A EG 20010167A EG 20010167 A EG20010167 A EG 20010167A EG 24073 A EG24073 A EG 24073A
Authority
EG
Egypt
Prior art keywords
pyrrolo
pyrimidin
dihydro
benzoyl
oxo
Prior art date
Application number
EG20010167A
Other languages
English (en)
Inventor
Erik C Chelius
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of EG24073A publication Critical patent/EG24073A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EG20010167A 2000-02-25 2001-02-21 A novel crystalline form of n-(4-(2-amino-4,7 dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid and process thereof EG24073A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25

Publications (1)

Publication Number Publication Date
EG24073A true EG24073A (en) 2008-05-11

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010167A EG24073A (en) 2000-02-25 2001-02-21 A novel crystalline form of n-(4-(2-amino-4,7 dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid and process thereof

Country Status (35)

Country Link
US (1) US7138521B2 (pl)
EP (1) EP1259513B1 (pl)
JP (1) JP4846158B2 (pl)
KR (1) KR100744917B1 (pl)
CN (1) CN1183135C (pl)
AR (1) AR029471A1 (pl)
AT (1) ATE249462T1 (pl)
AU (1) AU777047B2 (pl)
BR (1) BR0108604A (pl)
CA (1) CA2400155C (pl)
CO (1) CO5261585A1 (pl)
CZ (1) CZ303772B6 (pl)
DE (1) DE60100750T2 (pl)
DK (1) DK1259513T3 (pl)
DZ (1) DZ3283A1 (pl)
EA (1) EA004684B1 (pl)
EG (1) EG24073A (pl)
ES (1) ES2206403T3 (pl)
HR (1) HRP20020701B1 (pl)
HU (1) HU229704B1 (pl)
IL (2) IL150480A0 (pl)
MX (1) MXPA02008242A (pl)
MY (1) MY124784A (pl)
NO (1) NO323422B1 (pl)
NZ (1) NZ519796A (pl)
PE (1) PE20011082A1 (pl)
PL (1) PL208061B1 (pl)
PT (1) PT1259513E (pl)
SI (1) SI1259513T1 (pl)
SK (1) SK287375B6 (pl)
SV (1) SV2002000321A (pl)
TW (1) TWI237024B (pl)
UA (1) UA72791C2 (pl)
WO (1) WO2001062760A2 (pl)
ZA (1) ZA200205265B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
JP2008543973A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド ペメトレキセドの中間体の調製方法
ATE492547T1 (de) * 2006-08-14 2011-01-15 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure
JP2008543975A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
US8088919B2 (en) * 2006-08-14 2012-01-03 Sicor Inc. Crystalline forms of pemetrexed diacid and processes for the preparation thereof
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
KR20100014854A (ko) * 2007-04-03 2010-02-11 닥터 레디스 레보러터리즈 리미티드 페메트렉세드의 고체 형태
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (en) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
EP2334685A4 (en) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr AMORPHOUS PEMETREXED DISODIUM
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
WO2011064256A1 (en) 2009-11-24 2011-06-03 Azad Pharmaceutical Ingredients Ag A new crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
CN103459392B (zh) * 2011-03-25 2016-08-17 台湾神隆股份有限公司 一种制备培美曲塞盐的方法
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
CA2900088A1 (en) 2013-02-06 2014-08-14 Cipla Limited Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP2983649A1 (en) 2013-04-12 2016-02-17 Actavis Group PCT ehf Pemetrexed formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
EP3021849B1 (en) 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
EP3212193B1 (en) 2014-10-30 2026-04-15 ScinoPharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
ES2959975T3 (es) * 2017-10-10 2024-02-29 Sun Pharmaceutical Ind Ltd Forma de dosificación para infusión intravenosa de pemetrexed
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
US12246018B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
EP0923287A4 (en) * 1996-08-30 2001-08-01 Lilly Co Eli NON-CLASSIC PYRROLO (2,3-D) PYRIMIDINE ANTIFOLATE
AU740087B2 (en) * 1997-09-26 2001-11-01 Eli Lilly And Company Processes and intermediates useful to make antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
WO2001014379A2 (en) * 1999-08-23 2001-03-01 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
PT1259513E (pt) 2004-02-27
US20030216416A1 (en) 2003-11-20
ATE249462T1 (de) 2003-09-15
HUP0204232A2 (hu) 2003-04-28
TWI237024B (en) 2005-08-01
NO20023974D0 (no) 2002-08-21
CZ303772B6 (cs) 2013-05-02
US7138521B2 (en) 2006-11-21
SV2002000321A (es) 2002-07-16
WO2001062760A2 (en) 2001-08-30
DK1259513T3 (da) 2004-01-12
DE60100750D1 (de) 2003-10-16
UA72791C2 (uk) 2005-04-15
PE20011082A1 (es) 2001-10-22
HUP0204232A3 (en) 2006-01-30
HU229704B1 (en) 2014-05-28
CN1406238A (zh) 2003-03-26
HK1051856A1 (en) 2003-08-22
SK11862002A3 (sk) 2003-01-09
KR100744917B1 (ko) 2007-08-01
DZ3283A1 (fr) 2001-08-30
CA2400155A1 (en) 2001-08-30
BR0108604A (pt) 2002-11-19
MY124784A (en) 2006-07-31
EA200200905A1 (ru) 2003-02-27
IL150480A0 (en) 2002-12-01
PL208061B1 (pl) 2011-03-31
HRP20020701A2 (en) 2003-12-31
AU777047B2 (en) 2004-09-30
DE60100750T2 (de) 2004-07-29
SI1259513T1 (en) 2003-12-31
CZ20022875A3 (cs) 2003-02-12
CA2400155C (en) 2009-09-15
EP1259513B1 (en) 2003-09-10
NO20023974L (no) 2002-08-21
NO323422B1 (no) 2007-04-30
AU3445101A (en) 2001-09-03
JP4846158B2 (ja) 2011-12-28
PL356423A1 (pl) 2004-06-28
SK287375B6 (sk) 2010-08-09
ES2206403T3 (es) 2004-05-16
MXPA02008242A (es) 2002-11-29
WO2001062760A3 (en) 2001-12-06
JP2003530321A (ja) 2003-10-14
CO5261585A1 (es) 2003-03-31
HRP20020701B1 (en) 2011-02-28
EP1259513A2 (en) 2002-11-27
AR029471A1 (es) 2003-07-02
KR20020075449A (ko) 2002-10-04
CN1183135C (zh) 2005-01-05
NZ519796A (en) 2003-01-31
IL150480A (en) 2007-12-03
EA004684B1 (ru) 2004-06-24
ZA200205265B (en) 2003-11-11

Similar Documents

Publication Publication Date Title
SI1259513T1 (en) A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMIC ACID AND PROCESS THEREFOR
AU6890800A (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
NO20025756L (no) Ny krystallinsk og amorf form av en triazolo(4,5- D)pyrimidinforbindelse
HUP0204034A3 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
HUP0402129A3 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives, preparation thereof, compositions containing the same and processes for their use
AU2002338695A1 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives
SK1452000A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
AU7287201A (en) Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl)-4-morpholinobenzamide
MY122760A (en) Substantially crystalline form of melagatran
WO2001017959A3 (en) Vitronectin receptor antagonists
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
SG84585A1 (en) Novel substituted 1,2,4-trioxanes as antimalarial agents and a process of producing the substituted 1,2,4-trioxanes
GB0221515D0 (en) A novel process for the preparation of 3,3'-azo-bis (6-hydroxybenzoic acid) and its derivatives
PL343542A1 (en) Method of obtaining n-(5-cyclopropyl-1-quinolin-5-yl-1h-pyrazol-4-carbonyl) guanidine monomesilate, method of obtaining n-(5-cyclopropyl-1-quinolin-5-yl-1h-pyrazol-4-carbonyl) quanidine monomesilate, method of obtaining methyl ester of 5-cyclopropyl-1-quinolin-5-yl-1h-pyrazol-4-carboxylic acid and method of obtaining methyl 3-cyclopropyl-2-dimethylamino-3-oxopropionate
PL353165A1 (pl) Nowe pochodne kwasów karboksylowych, zawierające pierściesigma pirymidyny podstawiony w pozycjach 5,6, sposób ich wytwarzania i ich zastosowanie jakoantagonistów receptora endoteliny
AU2002330127A1 (en) Methods of using 69039, a novel human na/ca exchanger family member
HU0104286D0 (en) Process for producing 2-(benzyloxi)imino-malonic acid derivatives and the novel derivatives
AU2002213119A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
PL338759A1 (en) Novel diethylammonic derivatives of beta-(3,5)-di-t-butyl-4-hydroxy) phenylpropionic acid aminoester
ITMO20010203A0 (it) Metodo per la produzione di manufatti a mosaico e manufatto cosi' ottenibile
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
AU2001231744A1 (en) Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists
AU2002336293A1 (en) Novel glutamic acid receptor and utilization thereof
AU2002328088A8 (en) Crystalline aluminophosphate production process and crystalline aluminophosphate